Evidence map›Paper›PMID 42104846›Full record

ArticleJournal of cachexia, sarcopenia and muscle2026

RAGE Re-Expressed at Myofibre Level Drives Muscle Wasting in Cancer Conditions.

Sara Chiappalupi, Giulia Gentili, Laura Salvadori, Martina Paiella, Marcello Manfredi, Vittoria Federica Borrini, Kaamashri Mangar, Ann Marie Schmidt, Maurizio Muscaritoli, Francesca Riuzzi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sara ChiappalupiDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Giulia GentiliDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Laura SalvadoriInteruniversity Institute of Myology (IIM), Perugia, Italy.
Martina PaiellaDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Marcello ManfrediDepartment of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Vittoria Federica BorriniDepartment of Translational Medicine, University of Piemonte Orientale, Novara, Italy.
Kaamashri MangarDepartment of Medicine, NYU Grossman School of Medicine, New York, USA.
Ann Marie SchmidtDepartment of Medicine, NYU Grossman School of Medicine, New York, USA.
Maurizio MuscaritoliDepartment of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Francesca RiuzziDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.
Guglielmo SorciDepartment of Medicine and Surgery, University of Perugia, Perugia, Italy.ORCID 0000-0002-1973-9679

Funding

AIRC ID 24762Consorzio Interuniversitario per le Biotecnologie (CIB) CMPT195992Fondazione Veronesi fellowship
6 · The paper itself

Abstract

backgroundCancer cachexia (CC) is a highly debilitating syndrome characterized by loss of body and muscle weight affecting most advanced cancer patients. The receptor for advanced glycation end-products (RAGE) is expressed by several cell types and sustains the inflammatory response in acute and chronic diseases. Total ablation of RAGE (Ager

methodsUsing an HSA/Cre-loxP system, we generated a tamoxifen-inducible conditional Ager

resultsCompared with LLC-Ager

conclusionsOur data provide evidence that RAGE engagement at myofibre level drives loss of body and muscle weights and inflammation in cancer conditions. RAGE ablation in muscles confers resistance to CC through myofibre remodeling and glycolytic reprogramming. On the clinical side, the overexpression of RAGE is an early event in muscles of cancer patients, suggesting a role for RAGE in the onset of the cachectic syndrome. Thus, the molecular targeting of RAGE might be useful to counteract cachexia and prolong survival in cancer patients.

Indexed as

CachexiaMuscular AtrophyMyofibrilsNeoplasmsReceptor for Advanced Glycation End ProductsAnimalsDisease Models, AnimalHumansMiceMice, KnockoutMuscle, SkeletalReceptor for Advanced Glycation End Productsanimal modelscancer cachexiamuscle wastingmyofibre remodelingRAGE

Identifiers

PMID42104846
PMCPMC13156705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.